查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1425118

光化性角化症治疗市场－2024年至2029年预测

Actinic Keratosis Treatment Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 140 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

2022年光化性角化症治疗市场规模为82.51亿美元。

称为光化性角化症的癌前皮肤病变需要个别化护理，这可能导致治疗依从性差和结果不佳。关于个人化护理的资讯很少，特别是根据患者偏好和目标量身定制治疗以及促进患者和医疗保健提供者之间的共用决策。

皮肤癌盛行率增加

根据疾病管制与预防美国，最常见的癌症是皮肤癌。有关默克尔细胞癌和其他非上皮皮肤恶性的资料由中央癌症登记处收集。最常见的皮肤癌类型、基底细胞癌和鳞状细胞癌，中央癌症登记处收集的频率较低。根据医疗支出小组调查统计，每年有超过610万人接受基底细胞癌和鳞状细胞癌治疗，费用约89亿美元。因此，光化性角化症的病例正在增加。

治疗中的个人化光化性角化症治疗

在治疗慢性皮肤病时，患者对长期重复治疗方法的依从性对于治疗效果至关重要，这推动了光化性角化病治疗产业的发展。医疗保健提供者 (HCP) 可以从诊断的角度与患者合作，了解他们独特的目标、担忧和治疗期望，从而提供个人化护理。患者和 HCP 之间持续的共用决策可以提高依从性并优化治疗结果。

光化性角化症的治疗

AK 的治疗方法具有不同的功效和安全性，这推动了光化性角化症治疗市场的发展。治疗方法：「病变定向」（即治疗同一区域内的单一或极少数 AK 病变）和「病变定向」（即治疗临床上明显的病变且无病变）。作为一个针对整个周围区域有明显变化的区域）。治疗方法的选择通常是个别化的，并且始终取决于患者和病变的特征，尤其是老年人。这类 AK 患者经常有高血压、心血管疾病、糖尿病和神经功能障碍等合併症，在选择特定药物和确定患者坚持治疗的倾向时应考虑这些合併症。

雷射治疗日益普及

单一 AK 病灶和 FC 可以透过雷射治疗去除光损伤的表皮和真皮乳头或进​​行全面部皮肤表面定序。据报道，在 AK 治疗中，使用二氧化碳和掺铒钇铝石榴石进行完全定序雷射换肤作为单一疗法比部分烧蚀技术更有效，儘管癒合时间较长。根据国家医学图书馆的资料，雷射换肤单一疗法与 5-FU 和 30% TCA 一样有效，但不如 PDT 有效。平均而言，90% 的患者对治疗有反应，10-15% 的患者在 6 个月内復发。

在北美，光化性角化病治疗市场预计将稳定成长。

北美光化性角化病治疗市场预计将受到该地区光化性角化病患病率不断增加和研究措施的推动。专门从事医学皮肤病学的国际生物製药公司 Almirall SA (ALM) 进行的一项民意调查显示，85% 的参与者对光化性角化病 (AK) 一无所知。鳞状细胞癌 (SCC) 是第二常见的皮肤癌类型，可能是这种持续性皮肤病的结果。这项民意调查由 Almirall 对超过 2,500 名 35 岁及以上的人进行，旨在确定西班牙、德国、义大利、英国和美国公众对 AK 和皮肤健康的认识。

FDA核准光化性角化症治疗并进行临床试验

  • 2023 年 1 月，全球生物製药公司 Biofrontera AG 评估了 Amerous(R) 作为四肢、颈部和身体躯干光化性角化病(AK) 定点治疗的安全性和有效性。一项随机、双盲、安慰剂对照研究，多中心、3期临床试验已开始招募病患。
  • Almirall, SA 表示，2020 年 12 月，美国食品药物管理局(FDA)核准Klisyri®（tirbanibulin）用于局部治疗面部或头皮的光化性角化病(AK)。Almirall 是一家专门从事皮肤健康的全球生物製药公司。 Crysiri®（通用名：tilvanibrin）预计将于 2021 年第一季在美国上市。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表

第二章调查方法

  • 调查资料
  • 先决条件

第三章执行摘要

  • 研究亮点

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析

第五章光化性角化症治疗市场：依治疗分类

  • 介绍
  • 动态疗法
  • 外科手术
  • 外用药

第六章光化性角化症治疗市场：依药物类别

  • 介绍
  • NSAID
  • 核苷代谢抑制剂
  • 免疫反应调节剂
  • 照片增强剂

第七章光化性角化症治疗市场：依最终使用者分类

  • 介绍
  • 医院及肿瘤中心
  • 皮肤科诊所
  • 居家护理
  • 其他的

第八章光化性角化症治疗市场：依地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 其他的
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第九章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 供应商竞争力矩阵

第十章 公司简介

  • Almirall
  • Mayo Clinic
  • Cleveland Clinic
  • Aetna
  • Circle Health Group
  • Cedars-Sinai
  • Ievulan
  • Alta Vista Dermatology
  • Levulan
简介目录
Product Code: KSI061616205

The actinic keratosis treatment market was valued at US$8.251 billion in 2022.

Precancerous skin lesions called actinic keratoses require individualized care, which can lead to poor treatment adherence and subpar results. There is little information on personalizing care, especially when it comes to adjusting therapy to each patient's preferences and goals and promoting shared decision-making between patients and healthcare providers.

Growing prevalence of skin cancer

As per the Centers for Disease Control and Prevention, the most prevalent type of cancer is skin cancer. Data on Merkel cell carcinoma and other non-epithelial skin malignancies are gathered by central cancer registries. The most prevalent kinds of skin cancer, basal cell, and squamous cell carcinomas, do not often have information gathered by central cancer registries. According to statistics from the Medical Expenditure Panel Survey, over 6.1 million individuals receive treatment for basal cell and squamous cell carcinomas annually, at a cost of about $8.9 billion. This leads to growing cases of actinic keratosis.

Personalization in treatment actinic keratosis treatment

When treating chronic skin disorders, patients' compliance with lengthy, repeated treatment regimens is crucial to the efficacy of the treatment which is boosting the actinic keratosis treatment industry. Healthcare providers (HCPs) can collaborate with their patients from the moment of diagnosis to understand their unique objectives, concerns, and treatment expectations to provide individualized care. Maintaining continuous, shared decision-making between patients and HCPs can enhance adherence and optimize treatment results to ultimately improve patient satisfaction and QoL, given the life-long nature of AK and the necessity for recurrent treatment sessions.

Management of Actinic Keratosis

For the management of AK, several therapies with various effectiveness and safety profiles are made available which is fueling the actinic keratosis treatment market. Therapies are categorized as "lesion directed" (i.e., treatments are conducted on a single or very small number of AK lesions within the same location) or "field directed," which targets the FC, i.e., the clinically evident lesions and the entire surrounding area with subclinical alterations. The choice of therapy is often made on an individual basis and is always dependent on the traits of both the patient and the lesion, especially in senior individuals. When selecting a specific medication and determining the patient's propensity to adhere to treatment, comorbidities including hypertension, cardiovascular disease, diabetes, and neurological dysfunctions are frequently present in this group of AK patients.

Growing popularity of laser therapies

Single AK lesions and FC can be treated with laser therapy, which can remove the actinic-damaged epidermis and papillary dermis or cause a full-face skin resurfacing. Fully ablative laser resurfacing using carbon dioxide and erbium-doped yttrium aluminium garnet has been reported to be more efficient as monotherapy than fractional ablative methods for treating AK, despite lengthy healing durations. Data from the National Library of Medicine indicate that laser resurfacing monotherapy is equally effective as 5-FU and 30% TCA and less effective than PDT, even though larger sample numbers for clinical studies are required. 90% of patients respond to therapy on average, and 10-15% relapse within 6 months.

In North America, it is projected that the actinic keratosis treatment market will grow steadily.

The actinic keratosis treatment market in North America is anticipated to be fueled by the growing prevalence of actinic keratosis and research initiatives in the region. A poll conducted by the international biopharmaceutical firm Almirall S.A. (ALM), which specializes in medical dermatology, revealed that 85% of participants were ignorant of actinic keratosis (AK). Squamous cell carcinoma (SCC), the second most typical kind of skin cancer, can develop as a result of this persistent skin disorder. The poll, performed by Almirall with more than 2,500 participants over the age of 35, sought to ascertain the general public's degree of awareness of AK and skin-healthy practices in Spain, Germany, Italy, the United Kingdom, and the United States.

Actinic Keratosis Treatment Procedures

  • Freezing (Cryotherapy), Liquid nitrogen freezing can be used to eliminate actinic keratoses. The material is applied to the damaged skin by healthcare professionals, which results in blistering or peeling. The injured skin cells peel off as the skin heals, revealing fresh skin. The most frequent kind of treatment is cryotherapy.
  • Scrapping (Curettage), The injured cells are scraped out during this treatment using a tool called a curet. Electrosurgery, which uses a pencil-shaped device to cut and vaporize the afflicted tissue with an electric current, may be performed after scraping.
  • Photodynamic Therapy, The doctor may apply a chemical solution that is light-sensitive to the damaged skin before exposing it to a specific light to eradicate the actinic keratosis. Skin inflammation, swelling, and a burning feeling may be side effects of treatment.

FDA Approvals and Clinical Trials for Actinic Keratosis Drugs

  • In January 2023, a randomized, double-blind, placebo-controlled, multi-center Phase 3 clinical trial to assess the safety and effectiveness of Ameluz® in a field-directed treatment of actinic keratosis (AK) on the extremities, neck, and trunk began enrolling patients, according to Biofrontera AG, a global biopharmaceutical company.
  • In December 2020, The U.S. Food and Drug Administration (FDA) authorized Klisyri® (tirbanibulin) for the topical treatment of actinic keratosis (AK) of the face or scalp, according to Almirall, S.A., a worldwide biopharmaceutical business specializing in skin health. During the first quarter of 2021, Klisyri® (tirbanibulin) will be made available in the United States.

Market Key Developments

  • In December 2022, Ameluz® and BF-RhodoLED® are being sold in Finland owing to Biofrontera AG (ISIN: DE0006046113), a global biopharmaceutical firm, and its Scandinavian licensing partner Galenica AB, Malmo, Sweden.
  • In September 2021, the commercial launch of Klisyri® (tirbanibulin), which was approved by the European Commission and the UK Medicines & Healthcare products Regulatory Agency (MHRA) in July and August of 2021, respectively, for the topical treatment of actinic keratosis (AK) of the face and scalp in adults, was announced by Almirall S.A., a global biopharmaceutical company.

Segmentation:

By Therapy

  • Photodynamic Therapy
  • Surgery
  • Topical Medications

By Drug Class

  • NSAIDs
  • Nucleoside Metabolic Inhibitor
  • Immune Response Modifiers
  • Photoenhancers

By End-User

  • Hospitals and Oncology Centers
  • Dermatology Clinics
  • Homecare
  • Others

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Assumptions

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Force Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. ACTINIC KERATOSIS TREATMENT MARKET, BY THERAPY

  • 5.1. Introduction
  • 5.2. Photodynamic Therapy
  • 5.3. Surgery
  • 5.4. Topical Medications

6. ACTINIC KERATOSIS TREATMENT MARKET, BY DRUG CLASS

  • 6.1. Introduction
  • 6.2. NSAIDs
  • 6.3. Nucleoside Metabolic Inhibitor
  • 6.4. Immune Response Modifiers
  • 6.5. Photoenhancers

7. ACTINIC KERATOSIS TREATMENT MARKET, BY END-USER

  • 7.1. Introduction
  • 7.2. Hospitals and Oncology Centers
  • 7.3. Dermatology Clinics
  • 7.4. Homecare
  • 7.5. Others

8. ACTINIC KERATOSIS TREATMENT MARKET, BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. United Kingdom
    • 8.4.2. Germany
    • 8.4.3. France
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. The Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Israel
    • 8.5.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES

  • 10.1. Almirall
  • 10.2. Mayo Clinic
  • 10.3. Cleveland Clinic
  • 10.4. Aetna
  • 10.5. Circle Health Group
  • 10.6. Cedars-Sinai
  • 10.7. Ievulan
  • 10.8. Alta Vista Dermatology
  • 10.9. Levulan